MAPK inhibitors dynamically affect melanoma release of immune NKG2D-ligands, as soluble protein and extracellular vesicle-associated

被引:2
|
作者
Lopez-Borrego, Silvia [1 ]
Campos-Silva, Carmen [1 ]
Sandua, Amaia [2 ]
Camino, Tamara [3 ]
Tellez-Perez, Lucia [1 ,6 ]
Alegre, Estibaliz [2 ]
Beneitez, Alexandra [4 ]
Jara-Acevedo, Ricardo [4 ]
Paschen, Annette [5 ]
Pardo, Maria [3 ]
Gonzalez, Alvaro [2 ]
Vales-Gomez, Mar [1 ]
机构
[1] CSIC, Natl Ctr Biotechnol CNB, Dept Immunol & Oncol, Madrid, Spain
[2] Univ Navarra, Pamplona, Navarre, Spain
[3] Hlth Res Inst Santiago de Compostela IDIS, Santiago De Compostela, Galicia, Spain
[4] Immunostep, Salamanca, Spain
[5] Univ Hosp Essen, Clin Dermatol, Essen, North Rhinewest, Germany
[6] Cold Spring Harbor Labs, Sch Biol Sci, Cold Spring Harbor, NY USA
关键词
metastatic melanoma; targeted cancer therapy; immunomodulation; immune evasion; extracellular vesicles; metalloproteases; NKG2D LIGAND EXPRESSION; T-CELL RECOGNITION; RESISTANCE; SURVIVAL; THERAPY; DIFFERENTIATION; CYTOTOXICITY; COMBINATION; SENSITIVITY; ACTIVATION;
D O I
10.3389/fcell.2022.1055288
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Metastatic melanoma presents, in many cases, oncogenic mutations in BRAF, a MAPK involved in proliferation of tumour cells. BRAF inhibitors, used as therapy in patients with these mutations, often lead to tumour resistance and, thus, the use of MEK inhibitors was introduced in clinics. BRAFi/MEKi, a combination that has modestly increased overall survival in patients, has been proven to differentially affect immune ligands, such as NKG2D-ligands, in drug-sensitive vs. drug-resistant cells. However, the fact that NKG2D-ligands can be released as soluble molecules or in extracellular vesicles represents an additional level of complexity that has not been explored. Here we demonstrate that inhibition of MAPK using MEKi, and the combination of BRAFi with MEKi in vitro, modulates NKG2D-ligands in BRAF-mutant and WT melanoma cells, together with other NK activating ligands. These observations reinforce a role of the immune system in the generation of resistance to directed therapies and support the potential benefit of MAPK inhibition in combination with immunotherapies. Both soluble and EV-associated NKG2D-ligands, generally decreased in BRAF-mutant melanoma cell supernatants after MAPKi in vitro, replicating cell surface expression. Because potential NKG2D-ligand fluctuation during MAPKi treatment could have different consequences for the immune response, a pilot study to measure NKG2D-ligand variation in plasma or serum from metastatic melanoma patients, at different time points during MAPKi treatment, was performed. Not all NKG2D-ligands were equally detected. Further, EV detection did not parallel soluble protein. Altogether, our data confirm the heterogeneity between melanoma lesions, and suggest testing several NKG2D-ligands and other melanoma antigens in serum, both as soluble or vesicle-released proteins, to help classifying immune competence of patients.
引用
收藏
页数:20
相关论文
共 5 条
  • [1] NKG2D Ligands in Liquid Biopsy: The Importance of Soluble and Vesicle-Bound Proteins for Immune Modulation
    Campos-Silva, Carmen
    Lopez-Borrego, Silvia
    Felgueres, Maria Jose
    Esteso, Gloria
    Vales-Gomez, Mar
    CRITICAL REVIEWS IN IMMUNOLOGY, 2022, 42 (01) : 21 - 40
  • [2] Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients
    Maccalli, Cristina
    Giannarelli, Diana
    Chiarucci, Carla
    Cutaia, Ornella
    Giacobini, Gianluca
    Hendrickx, Wouter
    Amato, Giovanni
    Annesi, Diego
    Bedognetti, Davide
    Altomonte, Maresa
    Danielli, Riccardo
    Calabro, Luana
    Di Giacomo, Anna Maria
    Marincola, Francesco M.
    Parmiani, Giorgio
    Maio, Michele
    ONCOIMMUNOLOGY, 2017, 6 (07):
  • [3] Release of Soluble Ligands for the Activating NKG2D Receptor: One More Immune Evasion Strategy Evolved by HIV-1?
    Giuliani, Erica
    Vassena, Lia
    Cerboni, Cristina
    Doria, Margherita
    CURRENT DRUG TARGETS, 2016, 17 (01) : 54 - 64
  • [4] Peripheral Blood TCRβ Repertoire, IL15, IL2 and Soluble Ligands for NKG2D Activating Receptor Predict Efficacy of Immune Checkpoint Inhibitors in Lung Cancer
    Sesma, Andrea
    Pardo, Julian
    Isla, Dolores
    Galvez, Eva M.
    Gascon-Ruiz, Marta
    Martinez-Lostao, Luis
    Moratiel, Alba
    Pano-Pardo, J. Ramon
    Quilez, Elisa
    Torres-Ramon, Irene
    Yubero, Alfonso
    Zapata-Garcia, Maria
    Domingo, Maria Pilar
    Esteban, Patricia
    Pamplona, Rebeca Sanz
    Lastra, Rodrigo
    Ramirez-Labrada, Ariel
    CANCERS, 2024, 16 (16)
  • [5] Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
    Genova, Carlo
    Tasso, Roberta
    Rosa, Alessandra
    Rossi, Giovanni
    Reverberi, Daniele
    Fontana, Vincenzo
    Marconi, Silvia
    Croce, Michela
    Dal Bello, Maria Giovanna
    Dellepiane, Chiara
    Tagliamento, Marco
    Ciferri, Maria Chiara
    Zullo, Lodovica
    Fedeli, Alessandro
    Alama, Angela
    Cortese, Katia
    Gentili, Chiara
    Cella, Eugenia
    Anselmi, Giorgia
    Mora, Marco
    Barletta, Giulia
    Rijavec, Erika
    Grossi, Francesco
    Pronzato, Paolo
    Coco, Simona
    CELLS, 2023, 12 (06)